vs
Side-by-side financial comparison of Organogenesis Holdings Inc. (ORGO) and Third Coast Bancshares, Inc. (TCBX). Click either name above to swap in a different company.
Third Coast Bancshares, Inc. is the larger business by last-quarter revenue ($57.7M vs $37.2M, roughly 1.5× Organogenesis Holdings Inc.). Over the past eight quarters, Third Coast Bancshares, Inc.'s revenue compounded faster (17.5% CAGR vs -46.5%).
Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.
Third Coast Bancshares, Inc. is a regional financial holding company headquartered in the U.S. Gulf Coast region. It provides a full suite of commercial and retail banking services including deposit products, business and consumer loans, mortgage services, and wealth management solutions, serving local small and medium-sized enterprises, individual consumers, and community clients across Texas and surrounding areas.
ORGO vs TCBX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $57.7M |
| Net Profit | — | $16.4M |
| Gross Margin | 30.8% | — |
| Operating Margin | -185.1% | — |
| Net Margin | — | 28.4% |
| Revenue YoY | -57.1% | — |
| Net Profit YoY | — | 20.5% |
| EPS (diluted) | — | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $37.2M | $57.7M | ||
| Q4 25 | $225.6M | $56.5M | ||
| Q3 25 | $150.9M | $54.5M | ||
| Q2 25 | $101.0M | $52.0M | ||
| Q1 25 | $86.7M | $45.9M | ||
| Q4 24 | $126.7M | $46.3M | ||
| Q3 24 | $115.2M | $42.9M | ||
| Q2 24 | $130.2M | $41.7M |
| Q1 26 | — | $16.4M | ||
| Q4 25 | $43.7M | $17.9M | ||
| Q3 25 | $21.6M | $18.1M | ||
| Q2 25 | $-9.4M | $16.7M | ||
| Q1 25 | $-18.8M | $13.6M | ||
| Q4 24 | $7.7M | $13.7M | ||
| Q3 24 | $12.3M | $12.8M | ||
| Q2 24 | $-17.0M | $10.8M |
| Q1 26 | 30.8% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 72.6% | — | ||
| Q4 24 | 75.5% | — | ||
| Q3 24 | 76.7% | — | ||
| Q2 24 | 77.6% | — |
| Q1 26 | -185.1% | — | ||
| Q4 25 | 28.1% | 38.1% | ||
| Q3 25 | 13.7% | 41.9% | ||
| Q2 25 | -12.5% | 40.5% | ||
| Q1 25 | -30.9% | 37.8% | ||
| Q4 24 | 8.1% | 38.7% | ||
| Q3 24 | 5.4% | 37.9% | ||
| Q2 24 | -10.7% | 34.1% |
| Q1 26 | — | 28.4% | ||
| Q4 25 | 19.4% | 31.7% | ||
| Q3 25 | 14.3% | 33.1% | ||
| Q2 25 | -9.3% | 32.2% | ||
| Q1 25 | -21.7% | 29.6% | ||
| Q4 24 | 6.1% | 29.7% | ||
| Q3 24 | 10.7% | 29.8% | ||
| Q2 24 | -13.1% | 25.9% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $0.31 | $1.02 | ||
| Q3 25 | $0.11 | $1.03 | ||
| Q2 25 | $-0.10 | $0.96 | ||
| Q1 25 | $-0.17 | $0.78 | ||
| Q4 24 | $0.05 | $0.80 | ||
| Q3 24 | $0.09 | $0.74 | ||
| Q2 24 | $-0.13 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $91.4M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $650.5M |
| Total Assets | $520.0M | $6.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $91.4M | — | ||
| Q4 25 | $93.7M | $175.2M | ||
| Q3 25 | $63.7M | $116.4M | ||
| Q2 25 | $73.1M | $113.1M | ||
| Q1 25 | $110.0M | $219.0M | ||
| Q4 24 | $135.6M | $371.2M | ||
| Q3 24 | $94.3M | $258.2M | ||
| Q2 24 | $89.9M | $241.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $62.3M | — | ||
| Q2 24 | $63.8M | — |
| Q1 26 | — | $650.5M | ||
| Q4 25 | $300.1M | $531.0M | ||
| Q3 25 | $255.1M | $513.8M | ||
| Q2 25 | $233.2M | $496.1M | ||
| Q1 25 | $242.9M | $479.8M | ||
| Q4 24 | $262.9M | $460.7M | ||
| Q3 24 | $278.5M | $450.5M | ||
| Q2 24 | $263.5M | $435.0M |
| Q1 26 | $520.0M | $6.6B | ||
| Q4 25 | $598.7M | $5.3B | ||
| Q3 25 | $509.8M | $5.1B | ||
| Q2 25 | $461.1M | $4.9B | ||
| Q1 25 | $467.4M | $4.9B | ||
| Q4 24 | $497.9M | $4.9B | ||
| Q3 24 | $446.3M | $4.6B | ||
| Q2 24 | $443.2M | $4.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.22× | — | ||
| Q2 24 | 0.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ORGO
Segment breakdown not available.
TCBX
| Net Interest Income | $53.6M | 93% |
| Noninterest Income | $4.0M | 7% |
